Chronic sepsis mortality characterized by an individualized inflammatory response

Journal of Immunology

Volumn 179, Issue 1, 2007, Pages 623-630

  Osuchowski, Marcin F ^a   Welch, Kathy ^a   Yang, Huan ^b   Siddiqui, Javed ^a   Remick, Daniel G ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Institute for Medical Research at North Shore Long Island Jewish System ^*  (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNOMODULATION; INDIVIDUALIZATION; INFLAMMATION; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 34250848196     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.179.1.623     Document Type: Article

References (49)

1. Angus, D. C., W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29: 1303-1310.
2. Sands, K. E., D. W. Bates, P. N. Lanken, P. S. Graman, P. L. Hibberd, K. L. Kahn, J. Parsonnet, R. Panzer, E. J. Orav, D. R. Snydman, et al. 1997. Epidemiology of sepsis syndrome in 8 academic medical centers. J. Am. Med. Assoc. 278: 234-240.
3. Martin, G. S., D. M. Mannino, S. Eaton, and M. Moss. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348: 1546-1554.
4. Abraham, E., M. P. Glauser, T. Butler, J. Garbino, D. Gelmont, P. F. Laterre, K. Kudsk, H. A. Bruining, C. Otto, E. Tobin, et al. 1997. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: a randomized controlled multicenter trial: Ro 45-2081 study group. J. Am. Med. Assoc. 277: 1531-1538.
5. Abraham, E., P. F. Laterre, J. Garbino, S. Pingleton, T. Butler, T. Dugernier, B. Margolis, K. Kudsk, W. Zimmerli, P. Anderson, et al. 2001. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit. Care Med. 29: 503-510.
6. Fisher, C. J., Jr., J. M. Agosti, S. M. Opal, S. F. Lowry, R. A. Balk, J. C. Sadoff, E. Abraham, R. M. Schein, and E. Benjamin. 1996. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N. Engl. J. Med. 334: 1697-1702.
7. Fisher, C. J., Jr., J. F. Dhainaut, S. M. Opal, J. P. Pribble, R. A. Balk, G. J. Slotman, T. J. Iberti, E. C. Rackow, M. J. Shapiro, R. L. Greenman, et al. 1994. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial, phase III rhIL-1ra sepsis syndrome study group. J. Am. Med. Assoc. 271: 1836-1843.
8. Fisher, C. J., Jr., G. J. Slotman, S. M. Opal, J. P. Pribble, R. C. Bone, G. Emmanuel, D. Ng, D. C. Bloedow, and M. A. Catalano. 1994. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit. Care Med. 22: 12-21.
9. Eichacker, P. Q., C. Parent, A. Kalil, C. Esposito, X. Cui, S. M. Banks, E. P. Gerstenberger, Y. Fitz, R. L. Danner, and C. Natanson. 2002. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am. J. Respir. Crit. Care Med. 166: 1197-1205.
10. Knaus, W. A., F. E. Harrell, Jr., J. F. LaBrecque, D. P. Wagner, J. P. Pribble, E. A. Draper, C. J. Fisher, Jr., and L. Soll. 1996. Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis: the rhIL-1ra phase III sepsis syndrome study group. Crit. Care Med. 24: 46-56.
11. Groeneveld, A. B., A. N. Tacx, A. W. Bossink, G. J. van Mierlo, and C. E. Hack. 2003. Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection. Clin. Immunol. 106: 106-115.
12. Hack, C. E., E. R. De Groot, R. J. Felt-Bersma, J. H. Nuijens, R. J. Strack Van Schijndel, A. J. Eerenberg-Belmer, L. G. Thijs, and L. A. Aarden. 1989. Increased plasma levels of interleukin-6 in sepsis. Blood 74: 1704-1710.
13. Waage, A., P. Brandtzaeg, A. Halstensen, P. Kierulf, and T. Espevik. 1989. The complex pattern of cytokines in serum from patients with meningococcal septic shock: association between interleukin 6, interleukin 1, and fatal outcome. J. Exp. Med. 169: 333-338.
14. Osuchowski, M. F., K. Welch, J. Siddiqui, and D. G. Remick. 2006. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J. Immunol. 177: 1967-1974.
15. Remick, D. G., G. R. Bolgos, J. Siddiqui, J. Shin, and J. A. Nemzek. 2002. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17: 463-467.
16. Taniguchi, T., Y. Koido, J. Aiboshi, T. Yamashita, S. Suzaki, and A. Kurokawa. 1999. Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit. Care Med 27: 1262-1264.
17. Turnbull, I. R., P. Javadi, T. G. Buchman, R. S. Hotchkiss, I. E. Karl, and C. M. Coopersmith. 2004. Antibiotics improve survival in sepsis independent of injury severity but do not change mortality in mice with markedly elevated interleukin 6 levels. Shock 21: 121-125.
18. Vianna, R. C., R. N. Gomes, F. A. Bozza, R. T. Amancio, P. T. Bozza, C. M. David, and H. C. Castro-Faria-Neto. 2004. Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release. Shock 21: 115-120.
19. 2 afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit. Care Med. 32: 2173-2182.
20. Bone, R. C. 1996. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit. Care Med. 24: 1125-1128.
21. Oberholzer, A., C. Oberholzer, and L. L. Moldawer. 2001. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 16: 83-96.
22. Fisher, C. J., Jr., S. M. Opal, J. F. Dhainaut, S. Stephens, J. L. Zimmerman, P. Nightingale, S. J. Harris, R. M. Schein, E. A. Panacek, J. L. Vincent, et al. 1993. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis: the CB0006 sepsis syndrome study group. Crit. Care Med. 21: 318-327.
23. Xiao, H., J. Siddiqui, and D. G. Remick. 2006. Mechanisms of mortality in early and late sepsis. Infect. Immun. 74: 5227-5235.
24. Ayala, A., G. Y. Song, C. S. Chung, K. M. Redmond, and I. H. Chaudry. 2000. Immune depression in polymicrobial sepsis: the role of necrotic (injured) tissue and endotoxin. Crit. Care Med. 28: 2949-2955.
25. Wang, H., W. Li, J. Li, B. Rendon-Mitchell, M. Ochani, M. Ashok, L. Yang, H. Yang, K. J. Tracey, P. Wang, and A. E. Sama. 2006. The aqueous extract of a popular herbal nutrient supplement, Angelica sinensis, protects mice against lethal endotoxemia and sepsis. J. Nutr. 136: 360-365.
26. Yang, S., M. Zhou, I. H. Chaudry, and P. Wang. 2002. Novel approach to prevent the transition from the hyperdynamic phase to the hypodynamic phase of sepsis: role of adrenomedullin and adrenomedullin binding protein-1. Ann. Surg. 236: 625-633.
27. Ebong, S., D. Call, J. Nemzek, G. Bolgos, D. Newcomb, and D. Remick. 1999. Immunopathologic alterations in murine models of sepsis of increasing severity. Infect. Immun. 67: 6603-6610.
28. Ebong, S. J., D. R. Call, G. Bolgos, D. E. Newcomb, J. I. Granger, M. O'Reilly, and D. G. Remick. 1999. Immunopathologic responses to non-lethal sepsis. Shock 12: 118-126.
29. Liliensiek, B., M. A. Weigand, A. Bierhaus, W. Nicklas, M. Kasper, S. Hofer, J. Plachky, H. J. Grone, F. C. Kurschus, A. M. Schmidt, et al. 2004. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 113: 1641-1650.
30. Wesche-Soldato, D. E., C. S. Chung, J. Lomas-Neira, L. A. Doughty, S. H. Gregory, and A. Ayala. 2005. In vivo delivery of Caspase 8 or Fas siRNA improves the survival of septic mice. Blood 106: 2295-2301.
31. Wichterman, K. A., A. E. Baue, and I. H. Chaudry. 1980. Sepsis and septic shock: a review of laboratory models and a proposal. J. Surg. Res. 29: 189-201.
32. Knight, P. R., A. Sreekumar, J. Siddiqui, B. Laxman, S. Copeland, A. Chinnaiyan, and D. G. Remick. 2004. Development of a sensitive microarray immunoassay and comparison with standard enzyme-linked immunoassay for cytokine analysis. Shock 21: 26-30.
33. Wang, H., O. Bloom, M. Zhang, J. M. Vishnubhakat, M. Ombrellino, J. Che, A. Frazier, H. Yang, S. Ivanova, L. Borovikova, et al. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251.
34. Efron, B., and R. Tibshirani. 1993. An Introduction to the Bootstrap. Chapman and Hall, New York.
35. Lasko, T. A., J. G. Bhagwat, K. H. Zou, and L. Ohno-Machado. 2005. The use of receiver operating characteristic curves in biomedical informatics. J. Biomed. Inform. 38: 404-415.
36. Hotchkiss, R. S., and I. E. Karl. 2003. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348: 138-150.
37. Xiao, H., and D. G. Remick. 2005. Correction of perioperative hypothermia decreases experimental sepsis mortality by modulating the inflammatory response. Crit. Care Med. 33: 161-167.
38. Nemzek, J. A., H. Y. Xiao, A. E. Minard, G. L. Bolgos, and D. G. Remick. 2004. Humane endpoints in shock research. Shock 21: 17-25.
39. Wang, H., H. Liao, M. Ochani, M. Justiniani, X. Lin, L. Yang, Y. Al-Abed, H. Wang, C. Metz, E. J. Miller, et al. 2004. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat. Med. 10: 1216-1221.
40. Yang, H., M. Ochani, J. Li, X. Qiang, M. Tanovic, H. E. Harris, S. M. Susarla, L. Ulloa, H. Wang, R. DiRaimo, et al. 2004. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. USA 101: 296-301.
41. Deans, K. J., M. Haley, C. Natanson, P. Q. Eichacker, and P. C. Minneci. 2005. Novel therapies for sepsis: a review. J. Trauma 58: 867-874.
42. Sunden-Cullberg, J., A. Norrby-Teglund, A. Rouhiainen, H. Rauvala, G. Herman, K. J. Tracey, M. L. Lee, J. Andersson, L. Tokics, and C. J. Treutiger. 2005. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit. Care Med. 33: 564-573.
43. Newcomb, D., G. Bolgos, L. Green, and D. G. Remick. 1998. Antibiotic treatment influences outcome in murine sepsis: mediators of increased morbidity. Shock 10: 110-117.
44. Remick, D. G., and P. A. Ward. 2005. Evaluation of endotoxin models for the study of sepsis. Shock 24(Suppl. 1): 7-11.
45. Ayala, A., Z. K. Deol, D. L. Lehman, C. D. Herdon, and I. H. Chaudry. 1994. Polymicrobial sepsis but not low-dose endotoxin infusion causes decreased splenocyte IL-2/IFN-γ release while increasing IL-4/IL-10 production. J. Surg. Res. 56: 579-585.
46. Ayala, A., P. J. O'Neill, S. A. Uebele, C. D. Herdon, and I. H. Chaudry. 1997. Mechanism of splenic immunosuppression during sepsis: key role of Kupffer cell mediators. J. Trauma 42: 882-888.
47. Ayala, A., M. A. Urbanich, C. D. Herdon, and I. H. Chaudry. 1996. Is sepsis-induced apoptosis associated with macrophage dysfunction? J. Trauma 40: 568-573; discussion 573-564.
48. Newton, S., Y. Ding, C. S. Chung, Y. Chen, J. L. Lomas-Neira, and A. Ayala. 2004. Sepsis-induced changes in macrophage co-stimulatory molecule expression: CD86 as a regulator of anti-inflammatory IL-10 response. Surg. Infect. 5: 375-383.
49. Tschaikowsky, K., M. Hedwig-Geissing, A. Schiele, F. Bremer, M. Schywalsky, and J. Schuttler. 2002. Coincidence of pro- and anti-inflammatory responses in the early phase of severe sepsis: longitudinal study of mononuclear histocompatibility leukocyte antigen-DR expression, procalcitonin, C-reactive protein, and changes in T-cell subsets in septic and postoperative patients. Crit. Care Med. 30: 1015-1023.